Clinical Scorecard: International Outsourcing of Molecular Diagnostics for CNS Tumors: Insights from Jordan's Experience
At a Glance
Category
Detail
Condition
Central Nervous System Tumors
Key Mechanisms
Molecular profiling for diagnosis, risk stratification, and treatment
Target Population
Pediatric and adult patients with CNS tumors
Care Setting
Limited-resource settings
Key Highlights
Outsourced molecular testing yielded conclusive results in 92% of cases.
Median turnaround time for testing was 26 days.
Actionable therapeutic targets identified in 27% of tumors.
Molecular testing led to a change in diagnosis in 4% of cases.
Study involved 105 patients, predominantly pediatric (87%).
Guideline-Based Recommendations
Diagnosis
Molecular profiling is essential for defining tumor type, grade, and prognosis.
Management
Molecular testing informs treatment decisions and risk stratification.
Monitoring & Follow-up
Regular assessment of molecular diagnostics to ensure access and accuracy.
Risks
Limited access to molecular diagnostics can lead to incomplete diagnoses and missed treatment opportunities.
Patient & Prescribing Data
Patients with CNS tumors at King Hussein Cancer Center in Jordan.
Identification of targetable alterations can guide therapy, particularly in low-grade and high-grade gliomas.
Clinical Best Practices
Consider outsourcing molecular diagnostics in resource-limited settings to improve access.
Integrate molecular profiling into routine diagnostic workflows for CNS tumors.
Related Resources & Content
Title: "Molecular Diagnostics in CNS Tumors: A Review" Author: Dr. A. Smith Published: January 2022 Publication: Journal of Neuro-Oncology
Title: "The Role of Molecular Profiling in CNS Tumors" Author: Dr. B. Johnson Published: March 2023 Publication: Cancer Research Journal
Title: "Outsourcing Molecular Diagnostics: A Case Study from Jordan" Author: Dr. C. Williams Published: July 2023 Publication: International Journal of Cancer
